Skip to main content
    V

    Ventyx Biosciences Inc (VTYX)

    Official site

    BIOTECHNOLOGY

    $14.00
    +0.00 (+0.00%)

    Last updated: Mar 04, 2026 at 4:00 PM ET

    Ventyx Biosciences Inc (VTYX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 7, 2025. Financial statements from company filings, amounts in US dollars.

    Ventyx Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$135.12M, operating cash flow was -$130.87M and free cash flow was -$131.11M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$22.83M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $148.45M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Research and development$117.00M$175.77M$87.74M$58.48M$6.37M$3.55M
    Operating income-$148.45M-$207.99M-$113.14M-$67.15M-$7.05M-$4.18M
    Net income-$135.12M-$192.96M-$108.43M-$83.75M-$28.17M-$4.47M
    EBITDA-$147.10M-$207.05M-$112.63MN/AN/A-$1.00K
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0$1.45M$0$0$0$1.08M$0$0$0$0
    Gross profit$0$0$0$724.00K$0$0$0$673.00K$0$0$0-$150.00K
    Operating income-$24.87M-$29.33M-$30.10M-$32.42M-$38.55M-$35.71M-$41.77M-$50.35M-$57.95M-$57.15M-$42.55M-$38.57M
    Net income-$22.83M-$26.99M-$27.44M-$29.35M-$35.25M-$31.95M-$38.57M-$46.75M-$54.03M-$53.25M-$38.93M-$35.21M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $1.05M by $26.21M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$276.56M$277.69M$371.40M$291.48M$245.00K$349.00K
    Current assets$229.63M$264.35M$330.69M$263.02M$245.00K$349.00K
    Cash and equivalents$27.26M$51.58M$64.82M$70.79M$244.00K$309.00K
    Total liabilities$22.52M$33.77M$17.50M$12.28M$30.90M$4.48M
    Short-term debt$1.05M$1.00M$412.00KN/AN/AN/A
    Long-term debtN/AN/AN/AN/A$2.92M$3.85M
    Shareholder equity$254.04M$243.92M$353.89M$279.20M-$30.65M-$4.13M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$211.47M$230.01M$253.48M$276.56M$301.10M$309.19M$332.08M$277.69M$321.70M$348.76M$389.17M$371.40M
    Total liabilities$20.10M$20.63M$21.85M$22.52M$22.33M$28.40M$25.08M$33.77M$38.06M$20.96M$17.55M$17.50M
    Cash and equivalents$31.97M$32.30M$28.08M$27.26M$61.77M$40.92M$141.90M$51.58M$56.61M$51.72M$63.67M$64.82M
    Shareholder equity$191.36M$209.38M$231.63M$254.04M$278.77M$280.80M$307.00M$243.92M$283.64M$327.81M$371.62M$353.89M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$130.87M-$166.52M-$98.77M-$38.65M-$6.20M-$2.64M
    Capital expenditures$241.00K$514.00K$275.00K$262.00K$0$262.00K
    Free cash flow-$131.11M-$167.04M-$99.05M-$38.91M-$6.20M-$2.90M
    Investing cash flow-$15.51M$100.94M-$74.93M-$214.37M$0-$214.37M
    Financing cash flow$122.11M$53.33M$167.77M$323.55M$6.13M$2.95M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$17.51M-$21.28M-$25.72M-$23.25M-$35.46M-$24.54M-$47.63M-$51.66M-$34.66M-$49.28M-$30.92M-$47.26M
    Capital expenditures$50.00K$42.00K$16.00K$6.00K$0$60.00K$175.00K$211.00K$48.00K$195.00K$60.00K$112.00K
    Free cash flow-$17.56M-$21.32M-$25.73M-$23.25M-$35.46M-$24.60M-$47.80M-$51.87M-$34.71M-$49.48M-$30.98M-$47.38M
    Last 12 quarters

    Frequently Asked Questions About VTYX

    What is Ventyx Biosciences' annual revenue?

    Ventyx Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is Ventyx Biosciences profitable?

    No. Ventyx Biosciences reported net income of -$135.12M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does VTYX generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$130.87M minus capital expenditures of $241.00K produced free cash flow of -$131.11M.

    How much debt does Ventyx Biosciences have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $1.05M and cash and equivalents of $27.26M.